By the end of 2022, the global automated cell biology systems market is anticipated to be worth USD 14.1 Billion, and it will grow at a CAGR of 9.0% to reach an expected valuation of around USD 33.5 Billion by the year 2032. Infinite cell line cultures dominate the worldwide market in 2021, with a share of around 76.2%, according to a recent analysis by Future Market Insights.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 14.1 Billion |
| Market Value 2032 | USD 33.5 Billion |
| CAGR 2022 to 2032 | 9.0% |
| Market Share of Top 5 Countries | 62.3% |
| Key Market Players | Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company |
Compared to the widespread methods utilized in the second half of the twentieth century, modern cell cultivation techniques are not significantly different. Despite the fact that these techniques made it possible to comprehend a variety of biological processes and that they served as determining factors for applications like drug testing and tissue regeneration, they had a number of inherent drawbacks. In actuality, conventional cell culture systems necessitate numerous and intricate manual handling techniques, which restricts the consistency of the cultivation in terms of cell yield and activity.
Additionally, long-term cell maintenance is costly, time-consuming, and demands a lot of reagents, test samples, and work. By reducing the number of operator interventions, the shift to user-friendly automated devices would favor standardizing the cultivation process, cutting production costs, and shortening the time required for cell culture preparation, thus promoting market growth for automated cell biology systems.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market value for automated cell biology systems was approximately 65.8% of the overall ~USD 19.9 Billion global bioprocess technology market in 2021.
The sale of automated cell biology systems expanded at a CAGR of 6.6% from 2015 to 2021.
Technologies like microfluidics and lab-on-a-chip represent a strategic approach to support the shift to user-friendly automated equipment. By using microculture systems in place of conventional Petri plates and flasks for cellular tests, researchers have been able to minimize the number of reagents used while still achieving high-throughput cell generation and culture in a controlled setting.
The development of tissue engineering aims to increase the possibility of replacing tissue development for regenerating or restoring organ and tissue function. Tissue engineering technology has advanced significantly in recent years, and it is now widely used in domains other than medicine, such as organs-on-a-chip, bioelectronic devices, cultured meats, and so on.
Cell culture is the primary method used for tissue engineering manufacturing. Therefore, it is crucial for tissue engineering research to maintain high standards for cell culture settings.
Modern uses of analytical system automation include clinical, pharmacological, and biomedical environments. The automatic system has played a significant role in both qualitative and quantitative analysis. Optically driven, electrochemical, and mass spectroscopic approaches have all been used as analytical techniques. Robotic automation lowers the cost of analysis while providing high precision and high system throughput.
Numerous lab-on-chip advancements have been made for cell culture and certain other biomedical applications. A cell culture device indicates the viability of the cells, nutrient consumption, nutrient output in the fermentation process, and pharmacological effect.
Because of the aforementioned factors, it is anticipated that from 2022 to 2032, the global automated cell biology systems market will expand at a CAGR of 9.0%.
As automated cell culture, on-chip is widely acknowledged as a benchmark parameter in existing microfluidic systems for cell biology, and a plethora of studies have been documented in the literature. At the research laboratory level, the minimization and downsizing of additional peripheral equipment are considered a fundamental necessity for the utilization of automated devices in cell culture, coupled with the need for systems that are ready-to-use in a plug-and-play mode.
Currently, the use of micro-devices for fluidic control is limited to the use of relatively complicated, specialized, and bulky external equipment and macro-to-micro interface systems, necessitating the ongoing assistance of human operators to manage fluid flow in an unstandardized and manual manner.
The systematic application of a suitably integrated control system for accurate fluid handling in a remote control framework will significantly improve the usability and readout dependability of micro-bioreactors. This is crucial in automating cell culture techniques, reducing human involvement, and significantly lowering the number of connection tubes, intake and output ports, and bulky external equipment.
The adoption of such control systems is gaining traction, owing to the above-mentioned factors, and this is set to pose lucrative opportunities for growth within the global automated cell biology systems market during the forecasted years.
Cell-based therapies have the ability to provide a successful treatment for medical disorders that are presently incurable. Their widespread commercialization has been put at risk by constraints such as scaling up and automating labor-intensive research discoveries, high production costs, and batch variance in large-scale automated manufacturing.
Additionally, even though many cell culture labs employ automated tools to do away with manual duties like handling plates, highly-trained lab staff are still required to spend hours every day maintaining these devices. As a result, the majority of benchtop automation has limitations in terms of scaling in cell culture facilities.
Furthermore, the utilization of mammalian cell culture is quickly expanding. Even though the fundamental processes for sustaining cells are quite repeatable, the majority of cell culture operations are still done by hand.
Personnel is required to perform repetitive tasks for hours on end each day, and frequently they must come in after regular working hours to cater to the cells or modify their biology to accommodate the workload. Both the workflow's throughput and its ability to be tracked are limited by this dependence on manual steps.
With the above-mentioned factors, the market for automated cell biology systems experiences a restraint in growth.
With a market share of 89.8% in all of North America in 2021, the USA presently dominates the region and is expected to sustain this growth throughout the forecast period.
The increasing expenditure on Research and Development in the area can be attributed to the market's expansion. Additionally, the expansion of pharmaceutical firms and manufacturers in the area together with rising public awareness of stem cell therapy is anticipated to significantly contribute to the market's expansion. Additionally, it is predicted that the rising number of bone marrow and cord blood transplants across the region will favorably influence market growth.
China represents roughly 64.9% of the East Asia market in 2021, with growth at a lucrative CAGR of 13.7% throughout the forecast period. China has a significant demand for automation, according to the International Federation of Robotics (IFR). According to sales volume, China was one of the top five markets for industrial robots in 2015.
The China Robot Industry Alliance estimates that Chinese robot suppliers sold about 20,400 units in 2015, increasing their share of the global market from 25% to 29% from 2013 until 2015. With the growing wave in automation, as well as its adoption, China is posed to be a highly lucrative market for automated cell biology systems over the forecast period.
During the forecast years, Germany is projected to grow at a CAGR of nearly 7.2% in the global automated cell biology systems market. The European Medicinal Agency (EMA) granted the CliniMACS Prodigy platform approval for the commercial manufacturing process in 2018 for the customization of protocols, which is accomplished through modularity and flexible programming, allowing its use for a number of different cell types, including the development of CAR-T cells, macrophages, virus-specific T-cells, and dendritic cells. With the manufacturing of such capable platforms, Germany is set to aid with the growth of the overall market during the projected period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Automated cell counters (single function) are the leading segment as a product, hold approximately 34.6% market share in 2021, and are expected to present high growth at a CAGR of 8.1% throughout the forecast period. The benefit of using an automated cell counter is that it largely eliminates human bias from the cell counting process. They can count more cells and are frequently faster than manually counting, which improves statistical accuracy. Automated cell counters are also employed in research and clinical labs. They can be used on urine and blood samples to count the different cell types present or to evaluate the viability of a cultivated cell line for investigation.
Infinite cell line cultures hold a global market share of around 76.2%, in 2021. Infinite cell line cultures are more robust and convenient to work with than primary cells since they can reproduce indefinitely. Infinite cell line cultures are also convenient for researchers because they are less expensive, easier to use, and able to survive more stages than primary cells. Because cell lines have a limitless supply of material and are simple to alter and grow, they are preferred for multiple screenings.
Drug development holds a share of around 35.4% in 2021, and this segment is expected to display gradual growth over the forecast period. New scientific developments in basic research, drug development, drug discovery, and customized medicine applications are being driven by 3D cell cultures. To understand the full potential of the technology, researchers can operate more efficiently with complex reagents and precious cells with the aid of high throughput, automated liquid handling solutions.
Biopharmaceutical companies hold the highest market share value of 27.4% during the year 2021. Growing drug development activities propelled by the rising demand for personalized medicine will propel this segment in terms of growth during the projected years. With the standardization of laboratory protocols, as well as the utilization of automated systems for process control technologies during the production process, this segment gains a higher share among the rest of the end users within the global market.
Key players in the market present novel solutions for the lab automation processes for cell biology systems. Moreover, with increasing approvals from the regulatory authorities for software-based total lab automation systems, the key players are presented with an opportunistic outlook for growth during the forecast period.
Similarly, recent developments related to companies manufacturing automated cell biology systems have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Cell Culture, Application, End User, and Region |
| Key Companies Profiled | Thermo Fisher Scientific; Corning Incorporated; Merck KGaA; Lonza; Sartorius AG; Hitachi. Ltd; Nanoentek; ChemoMetec; Danaher corporation; Agilent Technologies; Perkin Elmer (Nexcelom Bioscience LLC.); F. Hoffmann-La Roche AG; SHIMADZU CORPORATION; Bio-Rad Laboratories; Miltenyi Biotec; Sinfonia Technology; SHIBUYA CORPORATION; Advanced Instruments; Cell Culture Company, LLC; BD; Hamilton Company |
| Pricing | Available upon Request |
The global automated cell biology systems market stands at USD 14.1 Billion in 2022 and is set to expand 2.4X over the next ten years.
The automated cell biology systems market is expected to reach USD 33.5 Billion by end of 2032 at a CAGR of 9.0%.
The growing geriatric population, the rising burden of chronic and infectious diseases, and rising Research and Development on novel biopharmaceuticals are some of the key trends in this market.
By region, North America holds the highest market share of around 37.4% by value, in 2021, in the global automated cell biology systems market.
Europe is projected to grow with a CAGR of 7.5% during the forecast period.
The USA, Germany, India, China, and the United Kingdom are the top five countries, which are expected to drive demand in the automated cell biology systems market.
Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company, are some of the key players in the automated cell biology systems industry.
From 2015 to 2021, the market for automated cell biology systems expanded at the rate of 6.6% CAGR.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
| Estimated Market Size (2024E) | USD 228.1 billion |
|---|---|
| Projected Market Value (2034F) | USD 440.7 billion |
| Value-based CAGR (2024 to 2034) | 6.8% |
| Market Size (2023) | USD 443.1 billion |
|---|---|
| Market Size (2033) | USD 778.7 billion |
| Market CAGR (2023 to 2033) | 5.8% |
| Expected Market Value in 2023 | USD 216.35 billion |
|---|---|
| Projected Market Value in 2033 | USD 355 billion |
| Growth Rate (2023 to 2033) | 5.08% |
| Market Estimated Market (2023) | USD 23.6 billion |
|---|---|
| Projected Market Value (2033) | USD 56.0 billion |
| Value-based CAGR (2023 to 2033) | 9.0% |
Explore Life Science & Biotechnology Insights
View Reports
Automated Cell Biology Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
